Baxter International stock (US0718131099): Monday analyst snapshot is unavailable

Baxter International opened the week with no verified named-bank analyst note in the provided search results. The stock is still listed on the NYSE, and the article below anchors the update in Baxter's U.S. home market.

Baxter International started the week without a verifiable named-bank analyst update in the available search results, so the same-day focus falls back to the stock's U.S. listing, current market context and company fundamentals. The shares trade on the NYSE under BAX, and the latest available market snapshot in the supplied results places the company at a roughly $9.7 billion market value as of May 29, 2026, according to Stock Analysis.

The home-country anchor remains the United States: Baxter is headquartered in Deerfield, Illinois, and is listed on the New York Stock Exchange, which keeps the name firmly in the domestic large-cap healthcare conversation. For a German audience, the nearest practical bridge is the U.S. primary listing rather than a separate local venue, because no verified German quote was available in the provided materials.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: BAX
• Sector/industry: Healthcare equipment and supplies
• Headquarters/country: Deerfield, Illinois, United States
• Core markets: United States and international hospital and renal care markets
• Key revenue drivers: Hospital products and renal products
• Home exchange/listing venue: New York Stock Exchange (BAX)
• Trading currency: USD

Baxter International: core business model

Baxter supplies hospital and renal care products, with its operating structure centered on hospital products and renal offerings rather than a broad consumer-health mix.

What banks and research houses say about Baxter International

No verified analyst coverage was identified at the time of publication.

That absence matters for a Monday module because the usual bank-note angle could not be built from the provided allowed-source results, so the update relies instead on listed-status context and the company's market footprint in the United States. The most recent market-cap reference in the search results also shows how investor focus has shifted toward valuation and trading context rather than a fresh sell-side catalyst, with Stock Analysis citing $9.7 billion as of May 29, 2026.

There was no positive evidence in the supplied sources that Baxter has been delisted, taken private or removed from trading, so the stock continues to be treated as actively listed on the NYSE under the system's default listing model. That keeps the current discussion in the normal listed-equity framework for U.S. healthcare names.

Conclusion

The day's key takeaway is simple: Baxter remains an actively listed U.S. healthcare stock, but the provided search results did not surface a verifiable named-bank analyst update to anchor Monday's usual snapshot. The next meaningful catalyst would likely come from a primary-company filing, a fresh sell-side note or a new earnings-related disclosure.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.